title: Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions.
abstract: Diffuse Lewy body disease (DLBD) is a degenerative disease of the nervous system, involving the brain stem, diencephalic nuclei and cerebral cortex, associated with abnormal a-synuclein aggregation and widespread formation of Lewy bodies and Lewy neurites. DLBD presents as pure forms (DLBDp) or in association with Alzheimer disease (AD) in the common forms (DLBDc). Several neurotransmitter abnormalities have been reported including those of the nigrostriatal and mesocorticolimbic dopaminergic system, and central noradrenergic, serotoninergic and cholinergic pathways. The present work examines metabotropic glutamate receptor (mGluR) expression and signaling in the frontal cortex of DLBDp and DLBDc cases in comparison with age-matched controls. Abnormal L-[3H]glutamate specific binding to group I and II mGluRs, and abnormal mGluR1 levels have been found in DLBD. This is associated with reduced expression levels of phospholipase C beta1 (PLCbeta1), the effector of group I mGluRs following protein G activation upon glutamate binding. Additional modification in the solubility of PLCbeta1 and reduced PLCbeta1 activity in pure and common DLBD further demonstrates for the first time abnormal mGluR signaling in the cerebral cortex in DLBD. In order to look for a possible link between abnormal mGluR signaling and a-synuclein accumulation in DLBD, immunoprecipitation studies have shown alpha-synuclein/PLCbeta1 binding in controls and decreased alpha-synuclein/PLCbeta1 binding in DLBD. This is accompanied by a shift in the distribution of a-synuclein, but not of PLCbeta1, in DLBD when compared with controls. Together, these results support the concept that abnormal a-synuclein in DLBD produces functional effects on cortical glutamatergic synapses, which are associated with reduced alpha-synuclein/PLCbeta1 interactions, and, therefore, that mGluRs are putative pharmacological targets in DLBD. Finally, these results emphasize the emergence of a functional neuropathology that has to be explored for a better understanding of the effects of abnormal protein interactions in degenerative diseases of the nervous system.
authors.affiliation: Instituto de Neuropatologia, Servicio de Anatomia Patológica, IDIBELL-Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Dalfó
authors.forename: J L
authors.initials: JL
authors.lastname: Albasanz
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: I
authors.initials: I
authors.lastname: Ferrer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002458:Cell Fractionation / Q000379:methods; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D005260:Female; D018698:Glutamic Acid / Q000493:pharmacokinetics; D006160:Guanosine Triphosphate / Q000494:pharmacology; D006801:Humans; D015151:Immunoblotting / Q000379:methods; D007150:Immunohistochemistry / Q000379:methods; D047468:Immunoprecipitation / Q000379:methods; D020961:Lewy Body Disease / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D018613:Microscopy, Confocal / Q000379:methods; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D011180:Postmortem Changes; D011392:Proline / Q000031:analogs & derivatives* / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D016318:Quisqualic Acid / Q000494:pharmacology; D011869:Radioligand Assay / Q000379:methods; D017470:Receptors, Glutamate / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*; D050825:Synaptosomal-Associated Protein 25; D051843:Synucleins; D014316:Tritium / Q000493:pharmacokinetics; D010738:Type C Phospholipases / Q000378:metabolism*; D051844:alpha-Synuclein
chemical_list: C114785:2-amino-4-phosphono-propinate; C097299:4-aminopyrrolidine-2,4-dicarboxylic acid; D018690:Excitatory Amino Acid Agonists; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; D011422:Propionates; D017470:Receptors, Glutamate; C494208:SNAP25 protein, human; C497604:SNCA protein, human; D050825:Synaptosomal-Associated Protein 25; D051843:Synucleins; D051844:alpha-Synuclein; D014316:Tritium; D018698:Glutamic Acid; D006160:Guanosine Triphosphate; D016318:Quisqualic Acid; D011392:Proline; D010738:Type C Phospholipases